

Resource Summary Report

Generated by [dkNET](#) on Aug 17, 2026

Brilliant Violet 421(TM) anti-human CD10

RRID:AB_2561833

Type: Antibody

Proper Citation

BioLegend Cat# 312218, RRID:AB_2561833

Antibody Information

URL: http://antibodyregistry.org/AB_2561833

Proper Citation: BioLegend Cat# 312218, RRID:AB_2561833

Target Antigen: CD10

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 421(TM) anti-human CD10

Description: This monoclonal targets CD10

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone HI10a

Antibody ID: AB_2561833

Vendor: BioLegend

Catalog Number: 312218

Alternative Catalog Numbers: 312217

Record Creation Time: 20250819T230549+0000

Record Last Update: 20250820T041624+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 421(TM) anti-human CD10.

No alerts have been found for Brilliant Violet 421(TM) anti-human CD10.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Mayama M, et al. (2026) Modeling human prenatal adrenocortical functional zonation dynamics from pluripotent stem cells. *Cell stem cell*, 33(3), 454.

Sakata Y, et al. (2022) Reconstitution of human adrenocortical specification and steroidogenesis using induced pluripotent stem cells. *Developmental cell*, 57(22), 2566.

Sutton HJ, et al. (2021) Atypical B cells are part of an alternative lineage of B cells that participates in responses to vaccination and infection in humans. *Cell reports*, 34(6), 108684.

Fraccarollo D, et al. (2021) Expansion of CD10neg neutrophils and CD14+HLA-DRneg/low monocytes driving proinflammatory responses in patients with acute myocardial infarction. *eLife*, 10.

Chen L, et al. (2018) CD56 Expression Marks Human Group 2 Innate Lymphoid Cell Divergence from a Shared NK Cell and Group 3 Innate Lymphoid Cell Developmental Pathway. *Immunity*, 49(3), 464.